Merit Medical Systems
OverviewSuggest Edit
Merit Medical Systems is a manufacturer and marketer of proprietary disposable medical devices used in a range of interventional, diagnostic, and therapeutic medical procedures. The company offers products in six core groups: peripheral intervention, cardiac intervention, cardiovascular and critical care, interventional oncology and spine, breast cancer localization and guidance, and endoscopy. Its major product types include vascular access systems, catheters, guide wires, accessories and implantation kits, inflation devices, biopsy products, drainage products, needles, arm boards, introducer sheaths, valves, syringes, medication labeling systems, sharps holders, protective containers, ultrasound delivery systems, tumor localization systems, non-vascular stents, dilation balloons, and specialty procedure products.
| Type | Public | |
| Founded | 1987 | |
| HQ | South Jordan, UT, US | Map |
| Website | merit.com | |
| Employee Ratings | More | |
| Overall Culture | D- | More |
Recent NewsAll News
- Merit Medical Systems to Announce Second Quarter Results on July 29, 2021
- Lifshitz Law Firm, P.C. Announces Investigations of Jeld-Wen Holding, Inc. (NYSE: JELD), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Vanda Pharmaceuticals, Inc. (NasdaqGS: VNDA)
- Bragar Eagel & Squire is Investigating Certain Officers and Directors of Merit Medical Systems, Clover Health, and Zoom on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NYSE: MMSI Shareholder Notice: Update in Lawsuit against Merit Medical Systems, Inc. announced by Shareholders Foundation
Key People/Management at Merit Medical Systems
Joe Wright
Ronald Frost
Raul Parra
Brian G. Lloyd
Fred Lampropoulos
Justin Lampropoulos
Merit Medical Systems Office Locations
Merit Medical Systems Financials and Metrics
Merit Medical Systems Revenue
| USD | |
|---|---|
Revenue (Q1, 2021) | 248.9m |
Gross profit (Q1, 2021) | 111.9m |
Gross profit margin (Q1, 2021), % | 45% |
Net income (Q1, 2021) | 11.0m |
EBIT (Q1, 2021) | 14.2m |
Market capitalization (9-Sept-2021) | 4.0b |
Closing stock price (9-Sept-2021) | 71.9 |
Cash (31-Mar-2021) | 58.5m |
EV | 4.4b |
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 203.0m | 224.8m | 221.7m | 238.3m | 255.5m | 243.0m | 243.5m | 218.4m | 244.0m | 248.9m |
Cost of goods sold | 115.0m | 124.8m | 119.6m | 133.7m | 143.6m | 138.9m | 139.7m | 134.2m | 142.0m | 137.0m |
Gross profit | 88.1m | 100.0m | 102.0m | 104.6m | 112.0m | 104.1m | 103.8m | 84.2m | 102.0m | 111.9m |
Gross profit Margin, % | 43% | 44% | 46% | 44% | 44% | 43% | 43% | 39% | 42% | 45% |
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 34.2m | 43.5m | 52.0m | 49.5m | 35.2m | 37.3m | 50.1m | 49.7m | 44.6m | 58.5m |
Accounts Receivable | 119.1m | 131.9m | 129.3m | 146.5m | 156.4m | 144.7m | 150.1m | 138.8m | 142.0m | 150.3m |
Prepaid Expenses | 10.4m | 12.1m | 11.7m | 11.2m | 12.3m | 17.6m | 16.3m | 13.9m | 15.6m | 13.6m |
Inventories | 166.7m | 169.3m | 181.4m | 198.9m | 203.0m | 216.8m | 227.8m | 221.4m | 209.1m | 200.3m |
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 5.3m | 16.2m | 32.8m | 6.2m | 13.1m | 9.7m | (3.2m) | (22.2m) | (25.2m) | 11.0m |
Depreciation and Amortization | 15.3m | 32.8m | 50.4m | 22.3m | 45.0m | 68.5m | 23.3m | 47.0m | 70.5m | 21.4m |
Inventories | (5.4m) | (7.2m) | (19.4m) | (1.3m) | (5.1m) | (19.3m) | (5.0m) | 2.3m | 15.7m | (3.4m) |
Accounts Payable | 8.4m | 15.8m | 15.9m | (878.0k) | 1.3m | (3.8m) | 4.3m | (3.9m) | (2.7m) | 4.2m |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 149.3k |
Debt/Equity | 0.4 x |
Debt/Assets | 0.3 x |
Financial Leverage | 1.6 x |
Merit Medical Systems Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Fibrovein Holdings Limited | August 01, 2019 | $13.7 m |
| Brightwater Medical Inc. | June 14, 2019 | $50 m |
| Vascular Insights LLC | December 14, 2018 | $60 m |
| Cianna Medical, Inc. | November 13, 2018 | |
| DFINE, Inc. | July 06, 2016 | $97.5 m |
| BioSphere Medical SA | May 13, 2010 | $96 m |
| Alveolus Inc. | March 17, 2009 | |
| Argon Medical Devices Netherlands BV | ||
| BioSphere Medical, Inc. | ||
| BioSphere Medical Japan, Inc. |
Merit Medical Systems Revenue Breakdown
Merit Medical Systems revenue breakdown by business segment: 96.6% from Cardiovascular and 3.4% from Other
Merit Medical Systems revenue breakdown by geographic segment: 57.9% from United States and 42.1% from International
Merit Medical Systems Cybersecurity Score
Merit Medical Systems Online and Social Media Presence
3.29k Twitter followers
Merit Medical Systems has 3.29k Twitter Followers. The number of followers has increased 0.3% month over month and increased 2.7% quarter over quarter
Merit Medical Systems's Trends
Twitter Engagement Stats for @MeritMedical
4.8k
Tweets
1.3k
Following
3.3k
Followers
84
Tweets last 30 days
0.8
Avg. likes per Tweet
61.9%
Tweets with engagement
Merit Medical Systems Company Culture
Overall Culture
D-
53/100
CEO Rating
F
52/100
Compensation
D-
46/100
Merit Medical Systems News and Updates
Merit Medical Systems to Announce Second Quarter Results on July 29, 2021
Lifshitz Law Firm, P.C. Announces Investigations of Jeld-Wen Holding, Inc. (NYSE: JELD), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Vanda Pharmaceuticals, Inc. (NasdaqGS: VNDA)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Merit Medical Systems, Clover Health, and Zoom on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NYSE: MMSI Shareholder Notice: Update in Lawsuit against Merit Medical Systems, Inc. announced by Shareholders Foundation
Lifshitz Law Firm, P.C. Announces Investigations of Inovio Pharmaceuticals, Inc. (NasdaqGS: INO), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Vanda Pharmaceuticals, Inc. (NasdaqGS: VNDA)
Merit Medical Systems to Announce First Quarter Results on April 29, 2021
Merit Medical Systems Blogs
ClariVein® OC 5-Year Follow-up Results: Good Occlusion Rate, No Major Complications
Meet the One-Vac™, Merit’s Newest Evacuated Drainage Bottle
A Physician’s Perspective on Wire-Free Localization
Continuing Education: Why It’s Vital to Improving Patient Care
Embosphere® Results in Less Inflammatory Response, Lower Rates of Analgesic Use Compared to PVA After UFE
Merit Brings Awareness to Men’s Health During the Month of June
Merit Medical Systems Frequently Asked Questions
When was Merit Medical Systems founded?
Merit Medical Systems was founded in 1987.
Who are Merit Medical Systems key executives?
Merit Medical Systems's key executives are Joe Wright, Ronald Frost and Raul Parra.
How many employees does Merit Medical Systems have?
Merit Medical Systems has 6,355 employees.
What is Merit Medical Systems revenue?
Latest Merit Medical Systems annual revenue is $963.9 m.
What is Merit Medical Systems revenue per employee?
Latest Merit Medical Systems revenue per employee is $151.7 k.
Who are Merit Medical Systems competitors?
Competitors of Merit Medical Systems include Wexler Surgical, Argon Medical Devices and AngioDynamics.
Where is Merit Medical Systems headquarters?
Merit Medical Systems headquarters is located at 1600 Merit Pkwy, South Jordan.
Where are Merit Medical Systems offices?
Merit Medical Systems has offices in South Jordan, Chester, Houston, Malvern and in 7 other locations.
How many offices does Merit Medical Systems have?
Merit Medical Systems has 11 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies